Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
10x Genomics's Sloan Ratio for the quarter that ended in Jun. 2026 was -17.72%.
As of Jun. 2026, 10x Genomics has a Sloan Ratio of -17.72%, indicating there is a warning stage of accrual build up.
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2026, 10x Genomics has a Sloan Ratio of -17.72%, indicating there is a warning stage of accrual build up.
10x Genomics Sloan Ratio % Related Terms
10x Genomics Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Sloan Ratio % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
10x Genomics's Sloan Ratio for the fiscal year that ended in Dec. 2025 is calculated as
10x Genomics's Net Income for the trailing twelve months (TTM) ended in Jun. 2026 was -27.472 (Sep. 2025 ) + -16.252 (Dec. 2025 ) + -13.47 (Mar. 2026 ) + -17.931 (Jun. 2026 ) = $-75.1 Mil.
10x Genomics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was 43.214 (Sep. 2025 ) + 40.777 (Dec. 2025 ) + 26.12 (Mar. 2026 ) + 16.974 (Jun. 2026 ) = $127.1 Mil.
10x Genomics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2026 was -8.801 (Sep. 2025 ) + -1.805 (Dec. 2025 ) + -1.311 (Mar. 2026 ) + -7.735 (Jun. 2026 ) = $-19.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a Sloan Ratio % of -17.72% as of Jun. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on 10x Genomics and its competitors.
Is 10x Genomics' Sloan Ratio % too high?
10x Genomics' current Sloan Ratio % is -17.72%. Overall, 10x Genomics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Sloan Ratio % compare to HNGE and WAY?
10x Genomics' Sloan Ratio % of -17.72% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Healthcare Providers & Services company?
A good Sloan Ratio % depends on the Healthcare Providers & Services industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on 10x Genomics and its competitors. 10x Genomics's current Sloan Ratio % is -17.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.78, compared to a current price of $58.57 — trading 211.9% above its estimated fair value. The current Sloan Ratio % is -17.72%. 10x Genomics' overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For 10x Genomics (TXG), the current Sloan Ratio % is -17.72% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $58.57 is trading 211.9% above its estimated GF Value™ of $18.78.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Sloan Ratio %: -17.72%
GF Value™: $18.78 vs. price of $58.57 (211.9% above fair value)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
61GF Score
Get the complete analysis for TXG
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
